Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01E in resectable non-small cell lung cancer
2023-509234-19-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoints: Pathological Complete Response and Percent Residual Viable Tumor. Planned start Mar 2025; status: authorised.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509234-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509234-19-00.